Class information for:
Level 1: DALFAMPRIDINE//FAMPRIDINE//4 AMINOPYRIDINE

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
19798 489 32.5 55%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
0 4 BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY 4064930
351 3       GAP JUNCTION//CONNEXIN//OLIGODENDROCYTE 35607
3086 2             NODE OF RANVIER//NERVE EXCITABILITY//AXON INITIAL SEGMENT 2369
19798 1                   DALFAMPRIDINE//FAMPRIDINE//4 AMINOPYRIDINE 489

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 DALFAMPRIDINE authKW 1147844 5% 74% 25
2 FAMPRIDINE authKW 1034554 6% 61% 27
3 4 AMINOPYRIDINE authKW 947466 20% 16% 97
4 FAMPRIDINE SR authKW 499548 2% 100% 8
5 AMPYRA authKW 187330 1% 100% 3
6 4 AMINOPYRIDINE DERIVATIVES authKW 124887 0% 100% 2
7 IMMEDIATE RELEASE FAMPRIDINE authKW 124887 0% 100% 2
8 3 4 DIAMINOPYRIDINE authKW 99398 2% 14% 11
9 3 HYDROXY 4 AMINOPYRIDINE authKW 62443 0% 100% 1
10 3 HYDROXY 4 AMINOPYRIDINE SULFATE authKW 62443 0% 100% 1

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 Pharmacology & Pharmacy 1860 37% 0% 180
2 Neurosciences 1062 28% 0% 139
3 Clinical Neurology 935 20% 0% 98
4 Physiology 231 8% 0% 41
5 Anesthesiology 87 3% 0% 14
6 Rehabilitation 58 3% 0% 13
7 Critical Care Medicine 37 2% 0% 10
8 Classics 26 1% 0% 3
9 Toxicology 23 3% 0% 14
10 Crystallography 17 2% 0% 11

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 DPT EMERGENCY MED 62443 0% 100% 1
2 INVEST FISIOL CELULAR NEUROC 62443 0% 100% 1
3 LOUIST STOKES CLEVELAND 62443 0% 100% 1
4 NEUROLCHIEF NEUROIMMUNOL UNIT 62443 0% 100% 1
5 PHARMACOL EXTERNAL SECT 62443 0% 100% 1
6 PHARMACOL MED GENET 62443 0% 100% 1
7 STANFORD MULTIPLE SCLEROSIS 62443 0% 100% 1
8 SUMMER FELLOWSHIP PROGRAM 62443 0% 100% 1
9 WALES CLIN 62443 0% 100% 1
10 PULM SECT 111JW 62441 0% 50% 2

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 ARCHIVES INTERNATIONALES DE PHARMACODYNAMIE ET DE THERAPIE 1757 2% 0% 8
2 THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS 1629 0% 1% 2
3 EUROPEAN JOURNAL OF PHARMACOLOGY 1471 5% 0% 26
4 JOURNAL OF NEUROTRAUMA 1115 2% 0% 8
5 JAPANESE JOURNAL OF PHYSIOLOGY 1074 1% 0% 6
6 JOURNAL OF NATURAL TOXINS 1054 0% 1% 2
7 ACTA PHARMACOLOGICA SINICA 883 2% 0% 9
8 PHARMACEUTICA ACTA HELVETIAE 803 1% 0% 3
9 SPINAL CORD 778 1% 0% 6
10 GENERAL PHARMACOLOGY 653 1% 0% 3

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 DALFAMPRIDINE 1147844 5% 74% 25 Search DALFAMPRIDINE Search DALFAMPRIDINE
2 FAMPRIDINE 1034554 6% 61% 27 Search FAMPRIDINE Search FAMPRIDINE
3 4 AMINOPYRIDINE 947466 20% 16% 97 Search 4+AMINOPYRIDINE Search 4+AMINOPYRIDINE
4 FAMPRIDINE SR 499548 2% 100% 8 Search FAMPRIDINE+SR Search FAMPRIDINE+SR
5 AMPYRA 187330 1% 100% 3 Search AMPYRA Search AMPYRA
6 4 AMINOPYRIDINE DERIVATIVES 124887 0% 100% 2 Search 4+AMINOPYRIDINE+DERIVATIVES Search 4+AMINOPYRIDINE+DERIVATIVES
7 IMMEDIATE RELEASE FAMPRIDINE 124887 0% 100% 2 Search IMMEDIATE+RELEASE+FAMPRIDINE Search IMMEDIATE+RELEASE+FAMPRIDINE
8 3 4 DIAMINOPYRIDINE 99398 2% 14% 11 Search 3+4+DIAMINOPYRIDINE Search 3+4+DIAMINOPYRIDINE
9 3 HYDROXY 4 AMINOPYRIDINE 62443 0% 100% 1 Search 3+HYDROXY+4+AMINOPYRIDINE Search 3+HYDROXY+4+AMINOPYRIDINE
10 3 HYDROXY 4 AMINOPYRIDINE SULFATE 62443 0% 100% 1 Search 3+HYDROXY+4+AMINOPYRIDINE+SULFATE Search 3+HYDROXY+4+AMINOPYRIDINE+SULFATE

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref.
in cl.		 Shr. of ref. in
cl.		 Citations
1 SHI, RY , SUN, WJ , (2011) POTASSIUM CHANNEL BLOCKERS AS AN EFFECTIVE TREATMENT TO RESTORE IMPULSE CONDUCTION IN INJURED AXONS.NEUROSCIENCE BULLETIN. VOL. 27. ISSUE 1. P. 36 -44 43 65% 9
2 OLBY, NJ , SMITH, DT , HUMPHREY, J , SPINAPOLICE, K , PARKE, N , MEHTA, PM , DISE, D , PAPICH, M , (2009) PHARMACOKINETICS OF 4-AMINOPYRIDINE DERIVATIVES IN DOGS.JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS. VOL. 32. ISSUE 5. P. 485 -491 31 94% 3
3 HAYES, KC , (2004) THE USE OF 4-AMINOPYRIDINE (FAMPRIDINE) IN DEMYELINATING DISORDERS.CNS DRUG REVIEWS. VOL. 10. ISSUE 4. P. 295-316 48 59% 34
4 SMITH, W , SWAN, S , MARBURY, T , HENNEY, H , (2010) SINGLE-DOSE PHARMACOKINETICS OF SUSTAINED-RELEASE FAMPRIDINE (FAMPRIDINE-SR) IN HEALTHY VOLUNTEERS AND ADULTS WITH RENAL IMPAIRMENT.JOURNAL OF CLINICAL PHARMACOLOGY. VOL. 50. ISSUE 2. P. 151-159 25 89% 24
5 BLIGHT, AR , HENNEY, HR , COHEN, R , (2014) DEVELOPMENT OF DALFAMPRIDINE, A NOVEL PHARMACOLOGIC APPROACH FOR TREATING WALKING IMPAIRMENT IN MULTIPLE SCLEROSIS.PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: WINNERS AND FINALISTS FOR THE PRIX GALIEN USA AWARDS 2013. VOL. 1329. ISSUE . P. 33 -44 38 54% 6
6 WEIR, S , TORKIN, R , HENNEY, HR , (2013) PHARMACOKINETIC PROFILE OF DALFAMPRIDINE EXTENDED RELEASE: CLINICAL RELEVANCE IN PATIENTS WITH MULTIPLE SCLEROSIS.CURRENT MEDICAL RESEARCH AND OPINION. VOL. 29. ISSUE 12. P. 1627-1636 28 78% 2
7 VOLLMER, T , BLIGHT, AR , HENNEY, HR , (2009) STEADY-STATE PHARMACOKINETICS AND TOLERABILITY OF ORALLY ADMINISTERED FAMPRIDINE SUSTAINED-RELEASE 10-MG TABLETS IN PATIENTS WITH MULTIPLE SCLEROSIS: A 2-WEEK, OPEN-LABEL, FOLLOW-UP STUDY.CLINICAL THERAPEUTICS. VOL. 31. ISSUE 10. P. 2215 -2223 24 96% 18
8 HAYES, KC , KATZ, MA , DEVANE, JG , HSIEH, JTC , WOLFE, DL , POTTER, RJ , BLIGHT, AR , (2003) PHARMACOKINETICS OF AN IMMEDIATE-RELEASE ORAL FORMULATION OF FAMPRIDINE (4-AMINOPYRIDINE) IN NORMAL SUBJECTS AND PATIENTS WITH SPINAL CORD INJURY.JOURNAL OF CLINICAL PHARMACOLOGY. VOL. 43. ISSUE 4. P. 379-385 33 80% 41
9 CORNBLATH, DR , BIENEN, EJ , BLIGHT, AR , (2012) THE SAFETY PROFILE OF DALFAMPRIDINE EXTENDED RELEASE IN MULTIPLE SCLEROSIS CLINICAL TRIALS.CLINICAL THERAPEUTICS. VOL. 34. ISSUE 5. P. 1056-1069 36 59% 8
10 VOLLMER, T , HENNEY, HR , (2009) PHARMACOKINETICS AND TOLERABILITY OF SINGLE ESCALATING DOSES OF FAMPRIDINE SUSTAINED-RELEASE TABLETS IN PATIENTS WITH MULTIPLE SCLEROSIS: A PHASE I-II, OPEN-LABEL TRIAL.CLINICAL THERAPEUTICS. VOL. 31. ISSUE 10. P. 2206 -2214 24 89% 19

Classes with closest relation at Level 1


Rank Class id link
1 10127 NERVE EXCITABILITY//AXONAL EXCITABILITY//THRESHOLD TRACKING
2 15703 LAMBERT EATON MYASTHENIC SYNDROME//SINGLE FIBER ELECTROMYOGRAPHY//REPETITIVE NERVE STIMULATION
3 36448 BACTERIAL FLAGELLUM FILAMENTS//INHIBITION CROSS CORRELATION//ISOLATED CENTRAL NERVOUS SYSTEM
4 33138 NICOTINIC ACETYLCHOLINE RECEPTORS PHEOCHROMOCYTOMA PC12 CELLS//PHARMACOL EXPTL MED//CATECHOLAMINE LEVEL
5 1796 MULTIPLE SCLEROSIS//KINESIOL COMMUNITY HLTH//MULTIPLE SCLEROSIS JOURNAL
6 7179 DENDROTOXIN//EPISODIC ATAXIA TYPE 1//KCNA1
7 22782 CEREBROCORTICAL SYNAPTOSOMES//GLUTAMATE EXOCYTOSIS//CEREBROCORTICAL NERVE TERMINALS
8 20809 END PLATE POTENTIAL//ICBAS PHARMACOL//H 3 ACETYLCHOLINE RELEASE
9 9426 PAROXYSMAL DEPOLARIZATION SHIFT//SEIZURE LIKE EVENTS//INTERICTAL BURSTING
10 21217 MULTIPLE SCLEROSIS//TONIC SPASM//PAINFUL TONIC SPASMS

Go to start page